Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 16Neoplasms 6Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1HER2+ Metastatic Breast Cancer (MBC) 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × neratinib × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡